Effects of the phosphodiesterase 4 inhibitor RPR 73401 in a model of immunological inflammation

被引:14
作者
Ehinger, AM [1 ]
Gorr, G [1 ]
Hoppmann, J [1 ]
Telser, E [1 ]
Ehinger, B [1 ]
Kietzmann, M [1 ]
机构
[1] Sch Vet Med, Inst Pharmacol Toxicol & Pharm, D-30559 Hannover, Germany
关键词
phosphodiesterase; 4; inhibitor; RPR; 73401; allergic dermatitis; ear swelling test; mouse; interleukin-4;
D O I
10.1016/S0014-2999(00)00116-3
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The study was performed to investigate effects of the phosphodiesterase 4 inhibitor RPR 73401 [N-(3,5-dichloropyrid-4-yl)-3-cyclopentyl-oxy-4-methoxybenzamid] on an allergic skin reaction. To simulate an immunological inflammation, BALB/c mice were sensitized to dinitrochlorobenzene or toluenediisocyanate. At first, the abdominal skin was shaved and 50 mu l Freund's adjuvant were injected intracutaneously once. Then, the horny layer was removed by adhesive tape stripping and 100 mu l 0.5% dinitrochlorobenzene or 5% toluenediisocyanate were administered on the epidermis for 4 days. After repeated local treatment of the ear skin with 20 mu l 3% RPR 73401 or intraperitoneal administration of 1 and 5 mg/kg RPR 73401, 20 mu l 1% dinitrochlorobenzene or 0.5% toluenediisocyanate were given topically as a challenge. The vehicle controls showed a high increase in ear thickness over 48 h after challenge, whereas RPR 73401 administered on either route reduced this increase significantly. Nevertheless after topical administration, RPR 73401 had a longer lasting effect. These and other results may point to an indication for RPR 73401 in immunological dermatitis. (C) 2000 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:93 / 99
页数:7
相关论文
共 40 条
[21]  
Kaiserlian D, 1999, EUR J DERMATOL, V9, P169
[22]  
Krasteva M, 1999, EUR J DERMATOL, V9, P65
[23]  
KUSTERS S, 1999, NAUNYNSCHMIEDEBER S3, V359, P325
[24]  
LOWRY OH, 1951, J BIOL CHEM, V193, P265
[25]  
Marx D., 1997, Journal of Allergy and Clinical Immunology, V99, pS444
[26]  
NICHOLSON CD, 1991, TRENDS PHARMACOL SCI, V12, P19, DOI 10.1016/0165-6147(91)90484-A
[27]  
Nuhn P, 1997, Pharm Unserer Zeit, V26, P238, DOI 10.1002/pauz.19970260508
[28]   Pharmacology of immunosuppressive drugs [J].
Olyaei, AJ ;
de Mattos, AM ;
Bennett, WM .
DRUGS OF TODAY, 1998, 34 (05) :463-479
[29]  
Palfreyman M N, 1996, Prog Med Chem, V33, P1, DOI 10.1016/S0079-6468(08)70302-3
[30]  
Palfreyman Malcolm N., 1995, Drugs of the Future, V20, P793